Secretory Immunoglobulin A Immunity in Chronic Obstructive Respiratory Diseases

Fays, Charlotte de; Carlier, François; Gohy, Sophie; Pilette, Charles

doi:10.3390/cells11081324

Cited by 22 publications

(25 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the generally well-known anti-pathogenic functions, SIgA mediates also important immunomodulatory effects on different mucosal immune cell types. Similar to monomeric serum IgA, it is proposed that the low affinity binding of SIgA to FcaRI, in absence of antigen, leads to immunomodulatory effects via inhibitory ITAMi signaling on mucosal effector leukocytes (Figure 1D) (2,74,89).…”

Section: During Inflammationmentioning

confidence: 99%

A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases

Bohländer

2023

Front. Immunol.

View full text Add to dashboard Cite

Inflammatory lung diseases represent a persistent burden for patients and the global healthcare system. The combination of high morbidity, (partially) high mortality and limited innovations in the last decades, have resulted in a great demand for new therapeutics. Are therapeutic IgA antibodies possibly a new hope in the treatment of inflammatory lung diseases? Current research increasingly unravels the elementary functions of IgA as protector against infections and as modulator of overwhelming inflammation. With a focus on IgA, this review describes the pathological alterations in mucosal immunity and how they contribute to chronic inflammation in the most common inflammatory lung diseases. The current knowledge of IgA functions in the circulation, and particularly in the respiratory mucosa, are summarized. The interplay between neutrophils and IgA seems to be key in control of inflammation. In addition, the hurdles and benefits of therapeutic IgA antibodies, as well as the currently known clinically used IgA preparations are described. The data highlighted here, together with upcoming research strategies aiming at circumventing the current pitfalls in IgA research may pave the way for this promising antibody class in the application of inflammatory lung diseases.

show abstract

Section: During Inflammationmentioning

confidence: 99%

A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases

Bohländer

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, the analysis of B cells from individuals with TACI mutations showed that human B cells were abolished in response to APRIL and BAFF during CSR induction to generate IgA but not IgG APRIL, and the interaction of BAFF with the BAFF-r receptor resulted in the production of both IgA and IgG [ 38 ]. In addition, the interaction of BAFF and APRIL with TACI in patients with chronic obstructive pulmonary disease prompted the CSR of IgA at the epithelial level [ 39 ]. BAFF and APRIL are expressed in the central nervous system following cytomegalovirus (CMV) and coronavirus infection and contribute to host resistance by sustaining virus-specific antibodies via the induction of TACI and BCMA receptors [ 40 ].…”

Section: Role Of Baff/april System In B-cell Response and Antibody Pr...mentioning

confidence: 99%

Considerations for Novel COVID-19 Mucosal Vaccine Development

Alturaiki

2022

Vaccines

View full text Add to dashboard Cite

Mucosal surfaces are the first contact sites of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses but provide limited mucosal immunity. Cytokine B-cell activation factor (BAFF) and A proliferation-inducing ligand (APRIL) in the tumor necrosis factor (TNF) superfamily play key immunological functions during B cell development and antibody production. Furthermore, homeostatic chemokines, such as C-X-C motif chemokine ligand 13 (CXCL13), chemokine (C–C motif) ligand 19 (CCL19), and CCL21, can induce B- and T-cell responses to infection and promote the formation of inducible bronchus-associated lymphoid tissues (iBALT), where specific local immune responses and memory cells are generated. We reviewed the role of BAFF, APRIL, CXCL13, CCL19, and CCL21 in the activation of local B-cell responses and antibody production, and the formation of iBALT in the lung following viral respiratory infections. We speculate that mucosal vaccines may offer more efficient protection against SARS-CoV-2 infection than systematic vaccines and hypothesize that a novel SARS-CoV-2 mRNA mucosal vaccine using BAFF/APRIL or CXCL13 as immunostimulants combined with the spike protein-encoding mRNA may enhance the efficiency of the local immune response and prevent the early stages of SARS-CoV-2 replication and the rapid viral clearance from the airways.

show abstract

“…While less studied in the respiratory tract compared to the gut mucosa, IgA appears to be important in homeostasis and controlling inflammation ( Sánchez Montalvo et al., 2022 ). IgA is produced as a dimer and transcytosed from the basal epithelial side to the apical surface by the polymeric immunoglobulin receptor (pIgR) to form S-IgA, which functions to neutralize many viral pathogens and some bacteria and with airway mucus play a role in agglutinating microorganisms ( Gohy et al., 2014 ; de Fays et al., 2022 ). Ciliated, goblet cells, and club cells express pIgR and importantly mucosal S-Ig-A is altered in both upper and lower airway diseases ( de Fays et al., 2022 ).…”

Section: Commonalities In the Respiratory Epithelial Microenvironmentmentioning

confidence: 99%

Biofilm aggregates and the host airway-microbial interface

Hall-Stoodley

McCoy

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Biofilms are multicellular microbial aggregates that can be associated with host mucosal epithelia in the airway, gut, and genitourinary tract. The host environment plays a critical role in the establishment of these microbial communities in both health and disease. These host mucosal microenvironments however are distinct histologically, functionally, and regarding nutrient availability. This review discusses the specific mucosal epithelial microenvironments lining the airway, focusing on: i) biofilms in the human respiratory tract and the unique airway microenvironments that make it exquisitely suited to defend against infection, and ii) how airway pathophysiology and dysfunctional barrier/clearance mechanisms due to genetic mutations, damage, and inflammation contribute to biofilm infections. The host cellular responses to infection that contribute to resolution or exacerbation, and insights about evaluating and therapeutically targeting airway-associated biofilm infections are briefly discussed. Since so many studies have focused on Pseudomonas aeruginosa in the context of cystic fibrosis (CF) or on Haemophilus influenzae in the context of upper and lower respiratory diseases, these bacteria are used as examples. However, there are notable differences in diseased airway microenvironments and the unique pathophysiology specific to the bacterial pathogens themselves.

show abstract

Secretory Immunoglobulin A Immunity in Chronic Obstructive Respiratory Diseases

Cited by 22 publications

References 152 publications

A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases

A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases

Considerations for Novel COVID-19 Mucosal Vaccine Development

Biofilm aggregates and the host airway-microbial interface

Contact Info

Product

Resources

About